JP2019510974A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510974A5
JP2019510974A5 JP2018549812A JP2018549812A JP2019510974A5 JP 2019510974 A5 JP2019510974 A5 JP 2019510974A5 JP 2018549812 A JP2018549812 A JP 2018549812A JP 2018549812 A JP2018549812 A JP 2018549812A JP 2019510974 A5 JP2019510974 A5 JP 2019510974A5
Authority
JP
Japan
Prior art keywords
nucleosome
subject
tissue
transcription factor
cofactor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018549812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510974A (ja
JP6777757B2 (ja
Filing date
Publication date
Priority claimed from GBGB1604806.8A external-priority patent/GB201604806D0/en
Application filed filed Critical
Publication of JP2019510974A publication Critical patent/JP2019510974A/ja
Publication of JP2019510974A5 publication Critical patent/JP2019510974A5/ja
Application granted granted Critical
Publication of JP6777757B2 publication Critical patent/JP6777757B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018549812A 2016-03-22 2017-03-22 癌検出のためのヌクレオソーム−転写因子複合体の使用 Active JP6777757B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1604806.8 2016-03-22
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Publications (3)

Publication Number Publication Date
JP2019510974A JP2019510974A (ja) 2019-04-18
JP2019510974A5 true JP2019510974A5 (https=) 2020-08-27
JP6777757B2 JP6777757B2 (ja) 2020-10-28

Family

ID=55968658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549812A Active JP6777757B2 (ja) 2016-03-22 2017-03-22 癌検出のためのヌクレオソーム−転写因子複合体の使用

Country Status (12)

Country Link
US (1) US20200363418A1 (https=)
EP (3) EP3433616B2 (https=)
JP (1) JP6777757B2 (https=)
KR (2) KR102246699B1 (https=)
CN (1) CN109313192B (https=)
AU (1) AU2017238442A1 (https=)
CA (1) CA3018428C (https=)
ES (2) ES2861440T5 (https=)
GB (1) GB201604806D0 (https=)
MY (1) MY187655A (https=)
SG (1) SG11201807991QA (https=)
WO (1) WO2017162755A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242130A (zh) * 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
US20240318259A1 (en) * 2021-09-24 2024-09-26 Oncocross Co., Ltd. Method for determining primary tumor site
WO2025073909A1 (en) 2023-10-04 2025-04-10 Belgian Volition Srl Pcr method for detecting ctcf occupied cfdna fragments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249548A1 (en) * 2000-03-27 2001-10-08 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
ES2399110T3 (es) * 2001-09-14 2013-03-25 F. Hoffmann-La Roche Ag Diagnóstico diferencial de los trastornos del metabolismo del hierro por medio de cuatro parámetros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
JP4873510B2 (ja) * 2008-07-01 2012-02-08 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
MY148542A (en) * 2009-06-15 2013-04-30 Cancer Res Initiatives Foundation A method for the assessment of cancer in a biological sample obtained from a subject
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
GB201303576D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers

Similar Documents

Publication Publication Date Title
Rozeman et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
JP2017215338A5 (https=)
CY1122871T1 (el) Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1
Yang et al. Predictors of severe and critical acute pancreatitis: a systematic review
JP2019510974A5 (https=)
JP2014529405A5 (https=)
Smadja et al. Placental growth factor level in plasma predicts COVID‐19 severity and in‐hospital mortality
RU2014112348A (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
RU2014112350A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
JP2016500110A5 (https=)
Zhao et al. The significance of RDW in patients with hepatocellular carcinoma after radical resection
JP2016513094A5 (https=)
JP2011526693A5 (https=)
Ondruschka et al. Post-mortem in situ stability of serum markers of cerebral damage and acute phase response
JP2014531573A5 (https=)
Gosselin et al. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban
JP2018529931A5 (https=)
JP2016118568A5 (https=)
Fischer et al. Serum amyloid A: a biomarker for renal cancer
JP2017508970A5 (https=)
JP2017504011A5 (https=)
JP2009516178A5 (https=)
Unruh et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype
Keskin et al. Prognostic value of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and multiphasic renal tomography findings in histological subtypes of renal cell carcinoma
Leong et al. Sampling circulating tumor cells for clinical benefits: how frequent?